All In MedTech

Device Trial Radar · NCT06655740

Safety, Tolerability, and Effectiveness of Duodenal Mucosal RF Vapor Ablation for Insulin Elimination in Type-2 Diabetes

A Pilot Human Study of the Safety, Tolerability and Effectiveness of the Aqua Medical Circumferential RF Vapor (RFV) Ablation System for Duodenal Mucosal Ablation for the Management of Insulin Requiring Type-2 Diabetes Mellitus

Last checked: Nov 20, 2026Latest source record: Nov 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

16

Planned (sponsor's estimate)

Start

Oct 1, 2024

Primary completion

Jun 30, 2027

Study completion Jul 31, 2027

Sponsor

Lead sponsor
Aqua Medical, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Oct 23, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether RFVA of the duodenal mucosa with or without the combination of Semaglutide is a safe and effective treatment to remove the need for insulin therapy among patients with T2D who are on stable doses of insulin.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • RF Vapor AblationDevice

    RF Vapor ablation of the duodenum

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety EndpointTime frame: 1 month
  2. Efficacy EndpointTime frame: 168 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinica Colonial

    Santiago, Chile

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.